Following the news that Synergen's potential treatment for severe sepsis Antril (anakinra) had shown lack of efficacy in Phase III clinical trials (Marketletter July 25), the company has announced that it is laying off 60% of its staff, around 375 positions, and will eliminate some operations and development activities. It has also closed the manufacturing plant in Boulder, Colorado, USA. These changes came into effect from August 1.
Of the 375 jobs to go, 340 are at Boulder and the remaining 35 are located in Europe and Japan. The Japanese office is closing, but a clinical group will be maintained in Europe to oversee the conduct of a Phase II trials of its interleukin-1 receptor antagonist for rheumatoid arthritis, said Synergen.
Synergen will keep on around 250 staff and retain its capabilities in discovery research, clinical development through the Phase II stage, and process development and manufacturing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze